Press Releases: December 2007 Archives
Under the leadership of Editor-in-chief Bernard M. Rosof, MD, Chair of the American Medical Association's Physician Consortium for Performance Improvement, Current Clinical Practice is poised to become a pivotal voice in the dialogue surrounding contemporary medicine. In addition to the latest trends in practice management, articles will address a range of topics including the patient-centered medical home, innovations in diagnostic and therapeutic technologies, and the cultivation of medical leadership.
"I am pleased to welcome you to Current Clinical Practice and introduce you to new information you can use immediately to facilitate the many overlapping tasks in a busy practice day," said Dr Rosof in his inaugural editorial. "This journal will assist you in optimizing patient care, in striving for best outcomes, and in contemplating new primary-care practice models."
The content of these journals also features continuing medical education (CME) modules developed through grants from industry and submitted by medical education companies. "We are delighted that the launch issue was a financial success, reinforcing our decision to provide a venue through which clinicians can obtain timely information along with free CME credits on a variety of subject matter," said Publisher Laura Dowden. "Look for the second issues of The Journal of Family Practice Special Edition: Current Clinical Practice and Current Clinical Practice in Spring 2008."
Dowden Health Media, a subsidiary of Lebhar-Friedman, Inc, publishes APCToday, Current Psychiatry, Contemporary Surgery, The Journal of Family Practice, Mayo Clinic Proceedings, and OBG Management. The company reaches millions of readers per month via print publications, Internet portals, and other outreach programs delivered through its four main divisions. The Professional Group focuses on professional medical journals and supplements. Dowden Custom Media serves the communication needs of hospitals and health systems. Medical Decision Point provides specialized educational programs for pharmaceutical companies. Finally, e-Crossings, the Internet and New Media Group, offers innovative solutions to industry. To learn more about Dowden Health Media go to http://www.dowdenhealth.com.
###
SOURCE Dowden Health Media
The Garibaldi Group team of Jeffrey J. Garibaldi, CCIM, president; Craig Zurick, senior vice president; and Matthew Kirby, senior vice president, are marketing the space on behalf of property owner, Livingston Circle Associates.
“Eisenhower Corporate Campus offers a unique opportunity for tenants looking for a headquarters location with first-class amenities in a highly strategic location,” stated Jeffrey Garibaldi. “With the northern New Jersey office market experiencing very low vacancies for large blocks of new generation space, Eisenhower Corporate Campus is one of the largest contiguous blocks of space remaining in the State providing the distinctive world-class working environment that is rarely available in this marketplace.”
According to Michael Schofel, principal, Eastman Management Corp., “Given the dynamics of the New York City office market, Eisenhower Corporate Campus is experiencing significant activity from corporations looking for cost effective operations in New Jersey.”
Eisenhower Corporate Campus may be divisible to full building wings with a minimum of 90,000 square feet. As a four-building design, it can be divided into two buildings with three floors each and two additional buildings with four floors each. The campus features connecting walkways located in the central atrium that provide easy access to every point in the campus.
Managed onsite by Eastman Management Corp., Eisenhower Corporate Campus is situated on 33.5 acres of beautifully landscaped grounds. The complex boasts unrivaled amenities including a 300-seat full-service cafeteria, fitness center, state-of-the-art teleconferencing auditorium, private underground executive parking and efficient and cost effective HVAC units.
Eisenhower Corporate Campus is surrounded by some of New Jersey’s most distinct and upscale residential communities, and it offers access to an exceptional labor pool, quality hotels, restaurants and business centers, first class health care providers and a variety of shopping and recreation opportunities. It provides direct access to Route 280 and is just minutes to Interstates 78, 80, 287 and the Garden State Parkway. Newark Liberty International Airport, Morristown Airport and the Hudson River crossings to New York City and mass transportation also are in close proximity to the site.
About The Eastman Companies
The Eastman Companies has been in business for over 28 years and is a recognized leader in high quality real-estate developments with property throughout northern New Jersey. Eastman is headquartered in Livingston and boasts a portfolio of more than two million sq. ft. of office, retail, and industrial space located in Morris, Essex, Bergen, and Burlington Counties.
About The Garibaldi Group
The Garibaldi Group is a full-service, global real estate firm now in its ninth decade of operation. With offices in Chatham and Princeton, New Jersey, as well as in Lehigh Valley, Pennsylvania, the firm’s extensive services include real estate consulting and brokerage services, financial services, lease administration, project management /development and property/construction management.
The Garibaldi Group is a member of CORFAC International, an organization of leading, privately-held, entrepreneurial commercial real estate firms serving 100 major markets in North America, and internationally through its King Sturge CORFAC International alliance.
For more information, please contact The Garibaldi Group/CORFAC International at 973-635-0303 or visit www.garibaldi.com.
About CORFAC International
Corporate Facility Advisors - CORFAC International is one of the largest commercial real estate services organizations in the world. CORFAC is comprised of privately held entrepreneurial firms serving more than 150 markets in The Americas and internationally through its King Sturge CORFAC International alliance.
Founded in 1989 and headquartered in Hollywood, Florida, CORFAC selects its partner firms based on their professional integrity, industry leadership, market coverage and high standards of excellence. CORFAC boasts one of the highest percentages of brokers with designations in professional associations in the industry.
Last year, CORFAC partner firms completed 11,500 commercial real estate transactions worldwide, encompassing 788 million square feet and valued at $23.4 billion. For more information on CORFAC contact the organization’s headquarters at 954-923-6160 or info@corfac.com or visit www.corfac.com.
The New York Academy of Medicine, founded in 1847, is an independent, non-partisan, non-profit institution whose mission is to enhance the health of the public through research, education, community engagement, and evidence-based advocacy.
Since the founding of the New York Academy of Medicine, Fellows have played an important role in the vibrancy of the institution. Today’s Fellows are leaders in the fields of law, social work, nursing, education and research as well as health and medicine.
In addition to the honor of being recognized by one’s peers, Fellowship in The New York Academy of Medicine provides many benefits including invitations to special lectureships and symposia, which create opportunities for Fellows to participate in discussions of issues relevant to enhancing the health and well-being of the public and of health-related professions. These events also provide Fellows with direct access to leaders in medicine, science, public health, health policy and health care delivery. Fellows are also invited to participate in Specialty and Interdisciplinary Sections of the Academy, which provide continuing medical education opportunities.
Mr. Horan is the current Chairman of the Greater New York Hospital Association, the Chairman of the Board of Directors of the Hospital Alliance of New Jersey, and is a member of the Board of Directors of the New Jersey Chamber of Commerce. He is a former Chairman of the Hospital Association of New York State. He was a member of the Board of Governors of the American College of Healthcare Executives and is a Fellow (FACHE) of that organization.
Mr. Horan joined Trinitas Hospital as President and Chief Executive Officer in July, 2001. He assumed that role just a year following the consolidation in January, 2000 of Elizabeth’s two hospitals, Elizabeth General Medical Center and St. Elizabeth Hospital.
From 1990 to 2001, Mr. Horan served as President and Chief Executive Officer of Our Lady of Mercy Healthcare System, Inc., Bronx, New York. Previously, he served as Vice President of Hospital Operations for New York University Medical Center, and as Executive Vice President of St. Vincent’s Medical Center of Richmond, New York.
A resident of Sea Girt, New Jersey, Mr. Horan earned his BS degree in Economics from St. Peter’s College, Jersey City, and his MA degree in Health Care Administration from The George Washington University, School of Government and Business, Department of Health Care Administration, Washington. DC.
###
About Trinitas Hospital
Trinitas Hospital is a major center for comprehensive health services for those who live and work in Central New Jersey. Offering 531 beds, Trinitas is distinguished by no less than ten Centers of Excellence, which include: the Trinitas Comprehensive Cancer Center; the Trinitas School of Nursing; the Center for Wound Healing & Hyperbaric Medicine; the Sleep Disorders Center; cardiology services, maternal/child health services; diabetes management; women’s services, renal care; behavioral health services, and senior services. The Department of Behavioral Health & Psychiatry offers one of the most comprehensive services in the state for the psychiatric treatment of children and adults. Trinitas serves as the Center for End-Stage Renal Care for Eastern Union County. Trinitas is a Catholic teaching hospital sponsored by the Sisters of Charity of Saint Elizabeth in partnership with Elizabethtown Healthcare Foundation. For more information on Trinitas Hospital visit: www.TrinitasHospital.org or call (908) 994-5138.
Kathryn Salamone, BA, MA
Manager, Public Relations & Marketing
Trinitas Hospital
225 Williamson Street
Elizabeth, New Jersey 07207
(908) 994 - 5139
(908) 994 - 5799 FAX
"This is an important step in our corporate rebuilding process to improve our operating margins and profitability," said MedQuist President and CEO Howard S. Hoffmann. "To remain a leader in our industry, we will continue to bring award-winning products to market, streamline processes, and look for new and innovative ways to service our customers."
Hoffmann added the reduction did not affect MedQuist's medical transcriptionist population, which at approximately 6,000, is the largest domestic medical transcriptionist workforce in the world.
About MedQuist
MedQuist is a leading provider of clinical documentation workflow solutions in support of the electronic health record. MedQuist provides electronic medical transcription, and health information and document management products and services, including digital dictation, speech recognition, Web-based transcription, electronic signature, medical coding, mobile dictation devices, and outsourcing services. For more information, please visit http://www.medquist.com.
Disclosure Regarding Forward-Looking Statements:
Some of the statements in this press release constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are not historical facts but rather are based on the Company's current expectations, estimates and projections regarding the Company's business, operations and other factors relating thereto. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expects," "intends," "plans," "projects," "believes," "estimates" and similar expressions are used to identify these forward-looking statements. The forward-looking statements contained in this press release include, without limitation, statements about the operating expense reductions associated with the Company's restructuring plan. These statements are only predictions and as such are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, including, without limitation, the risk that operating expenses are not reduced in accordance with the Company's expectations as a result of the implementation of the restructuring plan. For a discussion of these risks, uncertainties and assumptions, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of MedQuist Annual Report on Form 10-K for the year ended December 31, 2006, entitled "Risk Factors" and discussions of potential risks and uncertainties in MedQuist's subsequent filings with the SEC.
Issued – Wednesday 21 November 2007, London, UK, Philadelphia, PA & Liberty Corner, NJ - GlaxoSmithKline and Reliant Pharmaceuticals Inc. announced today that they had reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (£800 million) in cash.
Reliant, a privately held specialty pharmaceutical company focused on cardiovascular therapies, recorded net sales of $341 million in the nine months ending 30 September 2007, an increase of 62% over the comparable time period a year earlier.
GSK expects the transaction will be slightly accretive to earnings in 2008, excluding integration costs, and will create additional value in following years.
Through its strategic in-licensing and development strategy, Reliant has developed a portfolio of specialty medicines combating heart disease, including US rights to Lovaza™ (omega-3-acid ethyl esters), a treatment for adult patients with very high levels of triglycerides. Triglycerides are fatty substances in the blood associated with increased risks of coronary artery disease. Lovaza is indicated as an adjunct to diet to reduce triglyceride levels in adults with very high (³500 mg/dL) triglyceride levels.
High lipid levels continue to be a growing health problem in the United States, with up to 5 million people having triglyceride levels classified as very high. Lovaza is the only prescription omega-3 medicine approved by the US Food and Drug Administration for the treatment of very high triglycerides, and remains the only omega-3 medicine that, along with diet and exercise, has been clinically proven to provide a 45% reduction in triglycerides in adult patients with very high triglyceride levels.
Launched in late 2005, Lovaza (formerly known as Omacor®) achieved rapid uptake among patients and healthcare professionals. In the nine months ending 30 September 2007, net sales were $206 million, an increase of 115% over the first nine months of 2006.
Lovaza competes in the non-statin dyslipidemia segment of the UScardiovascular market, where it had achieved a 10% market share of total prescriptions as of 30 September 2007. Sales in the non-statin dyslipidemia market totaled approximately $2.2 billion in 2006 and are expected to grow in excess of 20% a year. GSK believes there is significant opportunity for future growth of Lovaza in this market segment.
Reliant licensed the rights to Lovaza in the USand Puerto Ricofrom Pronova BioPharma ASA (Oslo: PRON), a publicly traded Norwegian company that will continue to supply the product’s primary material. Rights to Lovaza in other markets have been licensed by Pronova to several other companies.
Commenting on the acquisition agreement, Chris Viehbacher, President, US Pharmaceuticals, GSK, said, “The addition of Lovaza to the GSK portfolio adds a new driver of sales growth in the USbusiness. It represents a strong strategic fit, complementing Coreg CR®, a leading treatment for heart failure and hypertension, and adds to our growing profile in the cardiovascular disease area.”
“Today is a momentous date for Reliant,” said Bradley T. Sheares, CEO of Reliant. “We are very proud of the work that our employees have done to build this company, particularly the energy and perseverance of our sales teams, who have demonstrated their worth in building a formidable Lovaza franchise in less than 24 months. We see great additional potential through this acquisition for Lovaza and the patients who could benefit from it.”
The acquisition is subject to approval by the US Federal Trade Commission and is expected to conclude before year-end.
In addition to Lovaza, Reliant Pharmaceuticals, based in Liberty Corner, NJ, currently markets three other in-licensed cardiovascular products – high blood pressure treatments DynaCirc CR® (isradipine) and InnoPran XL® (propanolol HCl), as well as Rythmol SR® (propafenone), which treats abnormal heart rhythms, or arrhythmia.
About GSK
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit www.gsk.com.
GlaxoSmithKline forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report on Form 20-F for 2006.
About Reliant Pharmaceuticals
Reliant Pharmaceuticals, Inc. is a pharmaceutical company that specializes in the development, commercialization and marketing of prescription therapeutic products. Reliant currently markets four cardiovascular products in the United Statesand focuses on promoting itsproducts to targeted primary care and specialty physicians, as well as selected hospitals and academic centers in the United States. Reliant’s sales force infrastructure is comprised of approximately 880 sales and marketing professionals nationwide.
Reliant Pharmaceuticals forward-looking statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, and other factors that may cause Reliant’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Reliant’s control and which could materially affect actual results, levels of activity, performance or achievements.
GlaxoSmithKline Enquiries:
UK Media enquiries: |
Philip Thomson |
(020) 8047 5502 |
|
|
Claire Brough |
(020) 8047 5502 |
|
|
Alice Hunt |
(020) 8047 5502 |
|
|
Joss Mathieson |
(020) 8047 5502 |
|
|
|
|
|
US Media enquiries: |
Nancy Pekarek |
(215) 751 7709 |
|
|
Mary Anne Rhyne |
(919) 483 2839 |
|
|
Rick Sluder |
(919) 483 2839 |
|
|
|
|
|
European Analyst/Investor enquiries: |
David Mawdsley |
(020) 8047 5564 |
|
|
Sally Ferguson |
(020) 8047 5543 |
|
|
|
|
|
US Analyst/ Investor enquiries: |
Frank Murdolo |
(215) 751 7002 |
|
|
Tom Curry |
(215) 751 5419 |
|
|
|
|
|
Reliant Enquiries: |
Marylou Rowe |
(908) 542 4646 |
Mevacor was introduced in the United States in 1987 by Merck as the first in a class of cholesterol-reducing medicines known as "statins". The U.S. patent for Mevacor expired in 2001.
Commenting on the agreement, JP Garnier, Chief Executive Officer, GlaxoSmithKline said: “This new partnership with Merck will enable GSK to address the important public health issue of high cholesterol and help patients better manage their health. OTC Mevacor will be a dynamic new addition to our fast-growing over-the-counter business and is further evidence of GSK’s ability to partner in new OTC switch opportunities.”
Richard T. Clark, Chief Executive Officer, Merck said: “With Mevacor, Merck pioneered the development of cholesterol-lowering medicines known as "statins" which are recognised worldwide and remain the standard of care today. We are pleased to be able to partner with GSK as a way to bring Mevacor directly to consumers in the U.S."
Application for OTC Mevacor to be reviewed by FDA
The new drug application (NDA) for OTC Mevacor will be reviewed by the U.S. Food and Drug Administration in a joint meeting of the Non-prescription Drugs Advisory Committee (NDAC) and the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) on 13 December 2007. The NDA, filed by Merck, is seeking approval of OTC Mevacor 20mg taken once daily to help lower cholesterol. OTC Mevacor 20mg is proposed for use in women age 55 and older and men age 45 and older with moderately elevated cholesterol and one or more heart disease risk factors.
About prescription Mevacor® (lovastatin)
Mevacor is a prescription medicine that is approved in the U.S. for the treatment of elevated cholesterol levels that lifestyle changes alone cannot control and to reduce the risk of first heart attack, unstable angina and coronary revascularisation procedures in healthy men and women with average or moderately elevated cholesterol levels.
According to the prescribing information, Mevacor should not be used by anyone allergic to any of its components, people with liver disease, or by women who are pregnant, breast-feeding or likely to become pregnant. It is recommended that liver function tests be performed in all patients prior to daily use of Mevacor 40mg or more.
Muscle pain or weakness in patients taking prescription Mevacor should be reported to a doctor because these could be signs of a serious side-effect. Patients should tell their doctors about other medications they are taking in order to avoid possible drug interactions.
The most common adverse events reported with Mevacor 20mg taken once a day were diarrhoea, flatulence, headache and myalgia.
Mevacor® (lovastatin) is a registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA
About GlaxoSmithKline
GlaxoSmithKline — one of the world’s leading research-based pharmaceutical and healthcare companies — is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
About GSK Consumer Healthcare
OTC Mevacor would be marketed in the US by GSK Consumer Healthcare, a GSK division with a well-established record of bringing informed access to OTC medicines.
In 1996, GSK Consumer Healthcare launched the first OTC nicotine replacement therapies, Nicorette and NicoDerm CQ, together with an innovative Committed Quitters behavioral support programme. Through increased access to GSK’s smoking cessation brands and support, more than five million adults in the United States have quit smoking.
In 2004, GSK Consumer Healthcare acquired the OTC marketing rights to orlistat in the USfrom the Roche Group (orlistat 120mg is marketed as the prescription product Xenical® by Roche). In June 2007, GSK Consumer Healthcare launched alli in the US, the first FDA-approved OTC weight control medicine. alli (orlistat 60mg) provides overweight adults a proven weight loss medicine and a comprehensive, tailored, behavioral support programme.
GSK’s education programmes provide consumers with information and the tools to support them through the behavioral modifications that are essential for their success with OTC medicines and that require long-term lifestyle changes.
Nicorette, NicoDerm CQ and alli trademarks are either owned by and/or licensed to GSK or associated companies. Xenical is a registered trademark of the Roche Group.
GSK forward-looking statement
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’s operations are described under ‘Risk Factors’ in the Operating and Financial Review and Prospects in the company’s Annual Report on Form 20-F for 2006.
About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programmes that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit http://www.merck.com.
Merck forward-looking statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.
##########
Enquiries:
|
UK Media enquiries: |
Philip Thomson |
(020) 8047 5502 |
|
|
Alice Hunt |
(020) 8047 5502 |
|
|
Joss Mathieson |
(020) 8047 5502 |
|
|
Claire Brough |
(020) 8047 5502 |
|
|
|
|
|
US Media enquiries: |
Nancy Pekarek |
(215) 751 7709 |
|
|
Mary Anne Rhyne |
(919) 483 2839 |
|
|
Brian Jones |
(215) 751 3415 |
|
European Analyst/Investor enquiries: |
David Mawdsley |
(020) 8047 5564 |
|
|
Sally Ferguson |
(020) 8047 5543 |
|
|
|
|
|
US Analyst/ Investor enquiries: |
Frank Murdolo |
(215) 751 7002 |
|
|
Tom Curry |
(215) 751 5419 |
West Caldwell, NJ, November 30, 2007 — Ricoh Americas Corporation announced today organizational changes throughout the company. Effective January 1, 2008, Norihisa “Nori” Goto, current vice chairman of the Company and President and CEO of Ricoh U.S., will become Chairman and CEO of Ricoh Americas Corporation. Goto will also continue his responsibilities as President and CEO of Ricoh U.S. Susumu “Sam” Ichioka, the current Chairman and CEO of Ricoh Americas Corporation, will be assuming a new significant position at the parent company Ricoh Company, Ltd., in Tokyo.
These organizational changes at Ricoh Americas Corporation are designed to make the company more efficient, cohesive and responsive to insure future growth. Goto and his team are prepared to lead Ricoh Americas Corporation to the next level, continuing to establish the company as one recognized for exceptional customer experiences and the undisputed leader in the market.
Additionally, Martin Brodigan, the former president of Ricoh Canada, Inc., will assume the role of Chief Financial Officer (CFO) of Ricoh Americas Corporation as of January 1. In this new role, Brodigan will consolidate the previous Ricoh U.S. and Ricoh Americas Corporation CFO roles into one position. Glenn Laverty, currently executive vice president of Direct Operations at Ricoh Canada, is also being promoted to President of Ricoh Canada.
Kyoji “Ken” Tokuhiro, currently General Manager, Business Strategy & Planning Center at Ricoh Company, Ltd., will lead the Strategy & Planning Office for Ricoh Americas Corporation. Kuni Minakawa, CFO of Ricoh Americas Corporation and Sam Hosoe, senior vice president of the Strategy & Planning Office will also be assuming new roles at the parent company in Japan.
As of January 1, Hideaki “Hugh” Urabe, the current senior vice president of Corporate Marketing for Ricoh Americas Corporation will become the President of Ricoh Latin America. At the same time, Kiyohshi “Kiyo” Shimizu the current President of Ricoh Latin America will be appointed senior vice president of Channel Development Strategy, in the Strategy & Planning Office.
Yoshimi Kobayashi, who is currently General Manager of the International Marketing Department, Multifunction Product Business Group, at Ricoh Company, Ltd., will become senior vice president of Corporate Marketing for Ricoh Americas Corporation. His task will be to consolidate the various marketing functions into one cohesive, efficient and highly functional group providing exceptional service to all channels. About Ricoh Americas Corporation
Ricoh Americas Corporation, headquartered in West Caldwell, N.J., is a subsidiary of Ricoh Company Ltd., the 71-year-old leading supplier of office automation equipment and electronics, with fiscal year 2006 sales in excess of $17 billion, an 8.4 percent increase over the previous year.
Ricoh Americas Corporation is a leading provider of document solutions. Ricoh’s fully integrated hardware and software products help businesses share information efficiently and effectively by enabling customers to control the input, management and output of documents. Ricoh’s line of document management devices include, color and black & white digital imaging systems, facsimile products, printers, scanners, digital duplicators, production printing products and wide format engineering systems. Additionally, Ricoh offers a wide variety of document and printing solutions directly and through strategic alliances enhancing office productivity and document workflow. Ricoh’s document management software enhances workgroup collaboration and offers secure storage, retrieval and sharing of critical information.
Ricoh Americas Corporation directly or through its network of authorized independent dealers markets and distributes products in North, Central and South America. For fiscal year 2006, Ricoh Americas Corporation sales exceeded $3.3 billion, an increase of 7.4 percent over the previous year.
Information about Ricoh's complete range of products and services can be accessed on the World Wide Web at www.ricoh-usa.com.
# # #
Contact:
Russell Marchetta
Ricoh Americas Corporation
(973) 882-2075
russell.marchetta@ricoh-usa.com
- Leadership in Place for CEO Transition on January 1 -
Madison, N.J., November 30, 2007 — Wyeth (NYSE: WYE) today announced senior management promotions of several executives who have been key contributors to Wyeth’s success over the past several years.
“As I prepare for the role of Chief Executive Officer in January, I am pleased to have these experienced executives in place to build on Wyeth’s strong foundation of success established by Bob Essner,” says Bernard Poussot, President and Chief Operating Officer, Wyeth. “As several successful leaders retire as planned from key positions, I am delighted that we have been able to develop and then promote talented successors from within our organization. This enables us to continue to build strength through core brands, invest in R&D, bring new products to market and manage costs – all key elements of Wyeth’s growth strategy.”
Joseph M. Mahady, President, Wyeth Pharmaceuticals
Joseph M. Mahady, 54, was elected to the position of President, Wyeth Pharmaceuticals and Senior Vice President, Wyeth, effective January 1, 2008. Mr. Mahady joined the Company in 1979 as a pharmacist in Regulatory Affairs. Following his progression through numerous management positions, he was appointed President, U.S. for Wyeth Pharmaceuticals in 1995. In 2003, Mr. Mahady assumed responsibility for all global business units. In 2005, he assumed responsibility for Latin America, and in February 2007 he was appointed President-Global Business, Wyeth Pharmaceuticals with responsibility for all worldwide commercial businesses.
“Under Joe’s leadership, our commercial success in the pharmaceuticals business has been key to Wyeth’s continuing revenue growth,” says Mr. Poussot. “It is the combination of his leadership, knowledge and passion for our business that makes him the ideal person to lead our pharmaceutical organization in a challenging environment.”
Mr. Mahady earned his pharmacy degree in 1977 from St. John’s University College of Pharmacy and his M.B.A. from Fairleigh Dickinson University in 1986.
Richard R. DeLuca, President, Fort Dodge Animal Health
Richard R. DeLuca, 45, was elected to the position of President, Fort Dodge Animal Health, effective January 1, 2008. Mr. DeLuca succeeds Mr. E. Thomas Corcoran, 60, who is retiring after serving as President of the Company’s animal health division for 23 years.
Mr. DeLuca, currently Chief Operating Officer at Fort Dodge Animal Health, has been with Wyeth since 1988. He has held positions of increasing responsibility, including Executive Vice President Finance/Administration and Chief Financial Officer at Fort Dodge; Vice President, Finance, Wyeth Research; and Vice President, Finance, Wyeth Pharmaceuticals. He holds a bachelor’s degree in business administration and accounting from Widener University.
“Rick is an accomplished leader who has made significant contributions to the growth and success of our animal health business. He brings a strong mix of leadership, operational experience and business knowledge to this position,” says Mr. Poussot.
Mr. Corcoran joined Fort Dodge Animal Health in 1985 as Division President. He was promoted to Vice President of Wyeth in 1993 with responsibility for the animal health and specialty pharmaceutical businesses. He is immediate past Chairman of The Animal Health Institute’s Executive Committee and of its Board of Directors.
Mr. Corcoran recently was named the recipient of two prestigious awards for his dedication to the animal health industry. He was honored with the 2007 Animal Pharm Lifetime Achievement Award, and then received the 2007 Leadership Award from Banfield, The Pet Hospital®. Both awards are given to an individual who makes significant changes and improvements to the animal health industry and profession.
“Tom has taken Fort Dodge from a small biologicals company to a growing organization recognized today as a global leader in the animal health industry that sells products in more than 100 countries,” says Mr. Poussot. “His dedication to innovative animal health research has helped develop important pharmaceutical products and vaccines.”
Cavan M. Redmond, President, Wyeth Consumer Healthcare
Cavan M. Redmond, 46, was promoted to the position of President, Wyeth Consumer Healthcare effective December 1, 2007. Mr. Redmond will be responsible for the division’s global operations. The Company also announced that Douglas A. Rogers, 47, has been named to the position of President, U.S. and Global New Business, Wyeth Consumer Healthcare.
Mr. Redmond has been serving as Executive Vice President and General Manager of the BioPharma business unit of Wyeth Pharmaceuticals. He also has held positions of increasing responsibility in the commercial and R&D organizations. Prior to joining Wyeth Pharmaceuticals, Mr. Redmond worked at Sandoz both in the United States and in Switzerland. He earned a bachelor’s degree in political science from the University of Maryland and a master’s degree in administration from The Johns Hopkins University. He also completed a post-graduate fellowship in organizational change management.
Most recently, Mr. Rogers served as President, Wyeth Consumer Healthcare, and prior to that, he served as President, Wyeth Consumer Healthcare, U.S. He joined Wyeth in November 1994 with the acquisition of American Cyanamid, where he was Vice President of Marketing for Lederle Consumer Health. Before that, he held various sales and marketing positions for Lederle Pharmaceuticals, Lederle Consumer Health, American Home Foods and Wyeth Consumer Healthcare. He holds a bachelor’s degree in journalism and an M.B.A., both from Lehigh University.
“Under Cavan’s leadership, Wyeth has become the third largest biotech company in the world. We know he’ll bring the same formula for success to our consumer brands,” says Mr. Poussot. “In addition, Doug’s marketing and commercial skills, coupled with his in-depth knowledge, energy and experience, will serve as a tremendous advantage for the division.”
Denise Peppard, Senior Vice President Human Resources, Wyeth
Denise Peppard, 50, was elected to the position of Senior Vice President Human Resources, Wyeth, effective January 1, 2008. Ms. Peppard succeeds René R. Lewin, 61, who is retiring after serving as the head of Wyeth Human Resources since 1994.
Ms. Peppard, currently Vice President, Corporate Human Resources, has been with Wyeth since 1999. She has held positions of increasing responsibility, including Senior Vice President of Human Resources for Wyeth Pharmaceuticals and Vice President of Human Resources for the North America pharmaceutical sales and marketing business.
“Denise has provided outstanding leadership to Wyeth’s pharmaceutical organization,” says Mr. Poussot. “She focused her efforts on facilitating positive change in our pharmaceutical business and has redefined the role of human resources through an increased business orientation. She will bring similar innovation to her new role.”
Prior to joining the Company, Ms. Peppard worked as Senior Director, Organization Development and Training at Parke-Davis in Ann Arbor, Michigan and as Vice President of Human Resources at a biotechnology start-up firm.
Ms. Peppard received a bachelor’s degree in business administration and accounting, as well as an M.B.A. with a dual concentration in organizational behavior and finance, from the University of Michigan.
Mr. Lewin joined Wyeth in 1994 as Vice President, Human Resources and was promoted to Senior Vice President in 2004. During his previous employment at Eli Lilly and Company, he held a variety of management positions, including President and General Manager, Eli Lilly Canada; Executive Director, Corporate Affairs; and Executive Director, Human Resources.
“René has served as the architect of Wyeth’s performance-based rewards culture and has had a tremendous impact on our success,” says Mr. Poussot. “Under his leadership, we have implemented innovative human resources strategies that recognized the changing needs of our workforce and our global business. These have included continuous process improvements, a robust global talent strategy and leadership development initiatives that are considered state-of-the-art in our industry. Through the strategic programs he has created, it is to René’s credit that we have been able to recruit, retain and develop top talent as exemplified by the executive transitions being announced today.”
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
######
Media
Douglas Petkus
Wyeth
973-660-5218
Investor
Justin Victoria
Wyeth
973-660-5340
